Shares of ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating) have received an average recommendation of “Buy” from the eight analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $75.00.
Several research firms recently issued reports on CCXI. StockNews.com began coverage on shares of ChemoCentryx in a research report on Thursday, March 31st. They issued a “sell” rating for the company. Stifel Nicolaus reissued a “buy” rating and issued a $85.00 price target on shares of ChemoCentryx in a research report on Friday, March 18th.
Several institutional investors have recently modified their holdings of CCXI. Total Clarity Wealth Management Inc. acquired a new stake in shares of ChemoCentryx in the fourth quarter valued at approximately $29,000. CWM LLC acquired a new stake in shares of ChemoCentryx in the fourth quarter valued at approximately $37,000. UMB Bank N A MO bought a new position in ChemoCentryx in the fourth quarter valued at approximately $37,000. Paragon Capital Management Ltd bought a new position in ChemoCentryx in the fourth quarter valued at approximately $42,000. Finally, US Bancorp DE boosted its stake in ChemoCentryx by 57.1% in the third quarter. US Bancorp DE now owns 3,083 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 1,121 shares during the last quarter. 70.58% of the stock is owned by institutional investors and hedge funds.
ChemoCentryx (NASDAQ:CCXI – Get Rating) last posted its quarterly earnings results on Tuesday, March 1st. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.01). ChemoCentryx had a negative return on equity of 40.75% and a negative net margin of 408.87%. The business had revenue of $2.32 million during the quarter, compared to analyst estimates of $3.49 million. During the same period last year, the company earned ($0.43) EPS. Sell-side analysts expect that ChemoCentryx will post -1.69 earnings per share for the current fiscal year.
ChemoCentryx Company Profile (Get Rating)
ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
- Get a free copy of the StockNews.com research report on ChemoCentryx (CCXI)
- Steel Dynamics Scales New Heights On Record Results
- Tesla (NASDAQ: TSLA) Stock Hits Four Figures Once Again
- The Institutions Are Driving Knight-Swift Transportation
- 3 Legendary Low-Beta Stocks Set to Outperform
- Affirm Stock Has Affirmed a Bottom
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.